| Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR D Drandi, L Kubiczkova-Besse, S Ferrero, N Dani, R Passera, B Mantoan, ... The Journal of Molecular Diagnostics 17 (6), 652-660, 2015 | 142 | 2015 |
| Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia D Rossi, C Lobetti Bodoni, E Genuardi, L Monitillo, D Drandi, M Cerri, ... Leukemia 23 (6), 1062-1072, 2009 | 117 | 2009 |
| Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program M Ladetto, C Lobetti-Bodoni, B Mantoan, M Ceccarelli, C Boccomini, ... Blood, The Journal of the American Society of Hematology 122 (23), 3759-3766, 2013 | 100 | 2013 |
| Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival S Ferrero, M Ladetto, D Drandi, F Cavallo, E Genuardi, M Urbano, ... Leukemia 29 (3), 689-695, 2015 | 95 | 2015 |
| Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia D Drandi, E Genuardi, I Dogliotti, M Ferrante, C Jiménez, F Guerrini, ... haematologica 103 (6), 1029, 2018 | 74 | 2018 |
| Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network D Drandi, M Alcantara, I Benmaad, A Söhlbrandt, L Lhermitte, ... Hemasphere 4 (2), e347, 2020 | 46 | 2020 |
| Next-generation sequencing for clinical management of multiple myeloma: ready for prime time? N Bolli, E Genuardi, B Ziccheddu, M Martello, S Oliva, C Terragna Frontiers in Oncology 10, 189, 2020 | 44 | 2020 |
| Early relapse risk in patients with newly diagnosed multiple myeloma characterized by next-generation sequencing M D'Agostino, GM Zaccaria, B Ziccheddu, EH Rustad, E Genuardi, ... Clinical Cancer Research 26 (18), 4832-4841, 2020 | 39 | 2020 |
| The minimal residual disease in non-Hodgkin's lymphomas: from the laboratory to the clinical practice S Galimberti, E Genuardi, F Mazziotta, L Iovino, F Morabito, S Grassi, ... Frontiers in oncology 9, 528, 2019 | 35 | 2019 |
| New molecular technologies for minimal residual disease evaluation in B-cell lymphoid malignancies I Dogliotti, D Drandi, E Genuardi, S Ferrero Journal of Clinical Medicine 7 (9), 288, 2018 | 32 | 2018 |
| Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders JP Stewart, J Gazdova, N Darzentas, D Wren, P Proszek, G Fazio, ... Blood Advances 5 (16), 3188-3198, 2021 | 29 | 2021 |
| Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma S Ferrero, L Monitillo, B Mantoan, D Barbero, E Genuardi, S Barbiero, ... Annals of hematology 92, 1503-1511, 2013 | 23 | 2013 |
| Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma patients S Oliva, E Genuardi, A Belotti, PMM Frascione, M Galli, A Capra, ... Blood 134, 4322, 2019 | 21 | 2019 |
| Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma C Lobetti-Bodoni, B Mantoan, L Monitillo, E Genuardi, D Drandi, ... Therapeutic Advances in Hematology 4 (3), 189-198, 2013 | 21 | 2013 |
| Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma S Ferrero, D Grimaldi, E Genuardi, D Drandi, GM Zaccaria, B Alessandria, ... Blood, The Journal of the American Society of Hematology 140 (12), 1378-1389, 2022 | 19 | 2022 |
| Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple … S Oliva, E Genuardi, A Belotti, PMM Frascione, M Galli, A Capra, ... Journal of Clinical Oncology 38 (15_suppl), 8533-8533, 2020 | 17 | 2020 |
| Telomeres and telomerase in normal and malignant B‐cells C Lobetti‐Bodoni, E Bernocco, E Genuardi, M Boccadoro, M Ladetto Hematological oncology 28 (4), 157-167, 2010 | 17 | 2010 |
| Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program M Ladetto, C Lobetti-Bodoni, B Mantoan, M Ceccarelli, C Boccomini, ... Blood 122 (23), 3759-3766, 2013 | 16 | 2013 |
| MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation M Ferrante, D Furlan, S Zibellini, M Borriero, C Candido, N Sahnane, ... Diagnostics 11 (5), 779, 2021 | 15 | 2021 |
| A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma S Oliva, L De Paoli, M Ruggeri, S Caltagirone, R Troia, D Oddolo, ... Annals of Hematology 100, 437-443, 2021 | 15 | 2021 |
